Search
2024
2023
-
Mar 18, 2024
CDE Clears IND Application for Therapeutic Candidate Targeting ATTRThe first in vivo gene editing drug using lipid nanoparticle to receive clinical approval in China
Read More
-
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPALeading the first clinical approval of an in vivo gene editing drug mediated by LNP in China
Read More
-
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing TechnologiesYolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Read More
-
Dec 17, 2023
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CMThe study by YolTech is a single-arm, open-label, dose-escalation clinical trial
Read More
